Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes
Public ClinicalTrials.gov record NCT01834274. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50 mg Compared With Sitagliptin 100 mg When Used in Combination With Metformin in Subjects With Type 2 Diabetes
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy of fasiglifam (TAK-875) plus metformin compared with sitagliptin plus metformin on glycemic control over a 24-week Treatment Period.
Study identification
- NCT ID
- NCT01834274
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 96 participants
Conditions and interventions
Conditions
Interventions
- Fasiglifam (TAK-875) Drug
- Fasiglifam (TAK-875) Placebo Drug
- Sitagliptin Drug
- Sitagliptin Placebo Drug
- Metformin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2013 (Type not available)
- Primary completion
- Mar 2014 (Actual)
- Completion
- Mar 2014 (Actual)
- Last update posted
- Sep 28, 2015
2013 – 2014
United States locations
- U.S. sites
- 44
- U.S. states
- 21
- U.S. cities
- 44
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Huntsville | Alabama | — | — |
| Not listed | Chandler | Arizona | — | — |
| Not listed | Glendale | Arizona | — | — |
| Not listed | Little Rock | Arkansas | — | — |
| Not listed | Fresno | California | — | — |
| Not listed | Garden Grove | California | — | — |
| Not listed | Modesto | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | Thousand Oaks | California | — | — |
| Not listed | Lakewood | Colorado | — | — |
| Not listed | Hallandale | Florida | — | — |
| Not listed | Hialeah | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Miami Lakes | Florida | — | — |
| Not listed | North Miami | Florida | — | — |
| Not listed | North Miami Beach | Florida | — | — |
| Not listed | Pembroke Pines | Florida | — | — |
| Not listed | Sanford | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Conyers | Georgia | — | — |
| Not listed | Evans | Georgia | — | — |
| Not listed | Boise | Idaho | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Evanston | Illinois | — | — |
| Not listed | Council Bluffs | Iowa | — | — |
| Not listed | Augusta | Kansas | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Durham | North Carolina | — | — |
| Not listed | Greensboro | North Carolina | — | — |
| Not listed | Hickory | North Carolina | — | — |
| Not listed | Carlisle | Ohio | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Medford | Oregon | — | — |
| Not listed | Fort Mill | South Carolina | — | — |
| Not listed | Laurens | South Carolina | — | — |
| Not listed | Spartanburg | South Carolina | — | — |
| Not listed | Knoxville | Tennessee | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Odessa | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Sugar Land | Texas | — | — |
| Not listed | Victoria | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 60 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01834274, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 28, 2015 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01834274 live on ClinicalTrials.gov.